FDA Approves First Brain-Penetrating Treatment for Hunter Syndrome in Nearly 20 Years

The FDA has approved Denali’s AVLAYAH, the first brain-penetrating enzyme therapy for Hunter syndrome (MPS II) in nearly 20 years.